SWOG clinical trial number
CTSU/A031701

A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

Open
Phase
II
Abbreviated Title
Phase II ddGC in mus-inv bladder cancer with bladder preservation for DDR
Status Notes
This study is active in SWOG effective 7/1/2020.
Activated
08/01/2018

Research committees

Genitourinary Cancer

Treatment

Cisplatin Gemcitabine hydrochloride

Eligibility Criteria Expand/Collapse

SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Other Clinical Trials

SWOG Clinical Trial Number
S1806

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.

Research Committee(s)
Genitourinary Cancer
Activated
04/19/2019
Accrual
17%
Open
Phase
III
SWOG Clinical Trial Number
S1802